Ralxifene is an estrogen agonist/antagonist indicated for:

• Treatment and prevention of osteoporosis in postmenopausal women. 
• Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. 
• Reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer. 

Important Limitations: Raloxifene is not indicated for the treatment of invasive breast cancer, reduction of the risk of recurrence of breast cancer, or reduction of risk of noninvasive breast cancer.

The recommended dosage is one 60 mg Raloxifene tablet daily, which may be administered any time of day without regard to meals 

Common adverse reactions associated with raloxifene include-

• Hot flashes
• Tiredness
• fatigue 
• nausea
• Fluid retention
• Skin rashes

Hot flash

Fatigue

Nausea

Edema

• Venous Thromboembolism: Increased risk of deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis. Discontinue use 72 hours prior to and during prolonged immobilization. 
• Death Due to Stroke: Increased risk of death due to stroke occurred in a trial in postmenopausal women with documented coronary heart disease or at increased risk for major coronary events. No increased risk of stroke was seen in this trial. Consider risk-benefit balance in women at risk for stroke. 
• Cardiovascular Disease: Raloxifene should not be used for the primary or secondary prevention of cardiovascular disease. 
• Premenopausal Women: Use is not recommended. 
• Hepatic Impairment: Use with caution. 
• Concomitant Use with Systemic Estrogens: Not recommended. 
• Hypertriglyceridemia: If previous treatment with estrogen resulted in hypertriglyceridemia, monitor serum triglycerides.